Biopharmaceutical Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Biopharmaceutical stocks.

Biopharmaceutical Stocks Recent News

Date Stock Title
Nov 22 INCY Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
Nov 21 INCY Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Nov 21 NAMS NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
Nov 21 ZYME Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21 ZYME FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20 NAMS NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
Nov 20 NAMS NewAmsterdam Pharma says late-stage trial for cholesterol drug succeeded
Nov 20 NAMS NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
Nov 20 TBPH Theravance Biopharma to Participate in an Upcoming Investor Conference
Nov 19 INCY Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
Nov 19 INCY Equity Markets Close Mixed Ahead of Nvidia Earnings
Nov 19 INCY S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
Nov 19 INCY Sector Update: Health Care Stocks Decline
Nov 19 INCY Top Midday Decliners
Nov 19 INCY Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
Nov 19 INCY Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
Nov 19 INCY Incyte seesaws on report of potential Merck takeover interest
Nov 19 INCY Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
Nov 19 INCY Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.
Nov 19 INCY Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Biopharmaceutical

A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.

Browse All Tags